超过初始反应:在髓状瘤恶性瘤中获得对低甲基化剂的耐药性
Brooke M Harvey1, Anoop K Enjeti2, Danielle R Bond3
1School of Biomedical Science and Pharmacy, The University of Newcastle, Callaghan, NSW, Australia.
Critical reviews in oncology/hematology
|February 23, 2026
概括
低甲基化剂 (HMA) 为患有急性骨髓性白血病 (AML) 和骨髓质综合征 (MDS) 的老年人提供了至关重要的治疗方法. 然而,对HMAs的耐药性导致复发,了解其机制对于开发新疗法至关重要.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
背景情况:
- 急性骨髓性白血病 (AML) 和骨髓显样性综合征 (MDS) 是重要的血液性恶性瘤.
- 这些疾病不成比例地影响老年患者,往往使他们无法接受化疗和干细胞移植等密集治疗.
- 低甲基化剂 (HMA) 是这些患者的基石疗法,提供了一种不那么密集的选择,可以诱导缓解并延长生存时间.
研究的目的:
- 为提供AML和MDS中HMA疗法的最新概述.
- 要突出HMA耐药性和疾病复发的关键挑战.
- 总结当前关于驱动获得的HMA抵抗的分子机制的知识.
主要方法:
- 对当前临床HMA在AML和MDS中的使用进行文献综述.
- 综合了关于HMA抵抗机制的数据.
- 分析与疾病复发相关的分子特征.
主要成果:
- 在AML和MDS中,HMA治疗提供了暂时的缓解,但最终受到不可避免的抗性和复发的限制.
- 获得的HMA抗性背后的机制是复杂的,并未完全理解.
- 了解这些机制对于开发针对HMA复发性疾病的有效策略至关重要.
结论:
- HMA对于老年患者的AML和MDS管理至关重要,但耐药性仍然是一个主要的临床障碍.
- 迫切需要进一步研究HMA耐药性的分子驱动因素.
- 开发用于HMA复发的AML和MDS的新型治疗方法是关键优先事项.
相关概念视频
Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Phase II Reactions: Methylation Reactions
805
Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
805
Abnormal Proliferation
5.3K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
Combination Therapies and Personalized Medicine
6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Adaptive Mechanisms in Cancer Cells
7.2K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.2K


